As seen in Figure 3E,F, the levels of phosphorylated AKT1 (p-AKT1) are decreased in CML cells treated with both compounds, compared to the untreated control. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.